Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice

@inproceedings{Thomas2016EpidermalGF,
  title={Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice},
  author={Riya Mary Thomas and Paulina Zuchowska and Alan W. J. Morris and Felecia M. Marottoli and Sangeeta Sunny and Ryan J. Deaton and Peter H. Gann and Leon M. Tai},
  booktitle={Acta neuropathologica communications},
  year={2016}
}
Cerebrovascular (CV) dysfunction is emerging as a critical component of Alzheimer's disease (AD), including altered CV coverage. Angiogenic growth factors (AGFs) are key for controlling CV coverage, especially during disease pathology. Therefore, evaluating the effects of AGFs in vivo can provide important information on the role of CV coverage in AD. We recently demonstrated that epidermal growth factor (EGF) prevents amyloid-beta (Aβ)-induced damage to brain endothelial cells in vitro. Here… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
EFAD mice express human APOE3 ( E3FAD ) or APOE4 ( E4FAD ) , overproduce human Aβ42 and are a well characterized model of APOE pathology .
EFAD mice express human APOE3 ( E3FAD ) or APOE4 ( E4FAD ) , overproduce human Aβ42 and are a well characterized model of APOE pathology .
EFAD mice express human APOE3 ( E3FAD ) or APOE4 ( E4FAD ) , overproduce human Aβ42 and are a well characterized model of APOE pathology .
EFAD mice express human APOE3 ( E3FAD ) or APOE4 ( E4FAD ) , overproduce human Aβ42 and are a well characterized model of APOE pathology .
All Topics